Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Belantamab mafodotin & Multiple Myeloma (MM) / Plasmocytoma

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

The first Antibody-Drug-Conjugates (ADCs) in Multiple Myeloma (MM) / Plasmocytoma, belantamab mafodotin, was approved in August 2020 as a monotherapy for patients with relapsed or refractory myeloma who have received at least four prior lines of therapy.
Maples et al. 2020 Expert Review of Anticancer Therapy 20: 1021-1035

…

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Lonial et al. 2020 Lancet Oncology 21: 207-221
Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma
Sheikh et al. 2020 Future Oncology 16: 2783–2798
Current developments in the combination therapy of relapsed/refractory multiple myeloma
Maples et al. 2020 Expert Review of Anticancer Therapy 20: 1021-1035
Review
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma
Tzogani et al. 2021

7/1/2026